Virpax Financial Statements From 2010 to 2024

VRPX Stock  USD 0.62  0.04  6.06%   
Virpax Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Virpax Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Virpax Pharmaceuticals financial statements helps investors assess Virpax Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Virpax Pharmaceuticals' valuation are summarized below:
Market Capitalization
3.2 M
Earnings Share
(13.25)
We have found one hundred twelve available fundamental trend indicators for Virpax Pharmaceuticals, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Virpax Pharmaceuticals current market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 8 M in 2024. Enterprise Value is likely to rise to about (12.8 M) in 2024
Check Virpax Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Virpax Pharmaceuticals' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 988 or Selling General Administrative of 6.1 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.03. Virpax financial statements analysis is a perfect complement when working with Virpax Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Virpax Pharmaceuticals Correlation against competitors.
For more information on how to buy Virpax Stock please use our How to Invest in Virpax Pharmaceuticals guide.

Virpax Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets12.7 M9.6 M5.5 M
Slightly volatile
Short and Long Term Debt Total1.2 M1.8 M898.8 K
Slightly volatile
Other Current Liabilities8.1 M7.7 M2.2 M
Slightly volatile
Total Current Liabilities8.1 M7.7 M2.6 M
Slightly volatile
Accounts Payable17.5418.46212.9 K
Slightly volatile
Cash11.9 M9.1 M5.2 M
Slightly volatile
Cash And Short Term Investments11.9 M9.1 M5.2 M
Slightly volatile
Common Stock Total Equity33.035.6530.1767
Slightly volatile
Common Stock Shares Outstanding1.3 M1.2 M3.4 M
Slightly volatile
Liabilities And Stockholders Equity12.7 M9.6 M5.5 M
Slightly volatile
Other Current Assets716.8 K486.8 K315.4 K
Slightly volatile
Other Stockholder Equity35.6 M61.5 M16.3 M
Slightly volatile
Total LiabilitiesM7.7 M2.4 M
Slightly volatile
Short and Long Term Debt846.5 K625.6 K591.2 K
Slightly volatile
Total Current Assets12.7 M9.6 M5.5 M
Slightly volatile
Capital Stock11.412.038.6267
Pretty Stable
Short Term Debt846.5 K625.6 K591.2 K
Slightly volatile
Common Stock11.412.038.6267
Pretty Stable
Inventory2.7 KK3.3 K
Slightly volatile
Non Currrent Assets Other313.9 K353.1 K384.5 K
Slightly volatile
Long Term Debt817.3 K919.4 KM
Slightly volatile
Deferred Long Term Liabilities313.9 K353.1 K384.5 K
Slightly volatile

Virpax Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative6.1 M7.8 M3.4 M
Slightly volatile
Other Operating Expenses10.8 M15.2 M6.1 M
Slightly volatile
Research Development4.4 M5.1 M2.5 M
Slightly volatile
Total Operating Expenses10.8 M15.2 M6.1 M
Slightly volatile
Depreciation And Amortization10.5 M12.9 M3.9 M
Slightly volatile
Selling And Marketing Expenses8.4 B9.5 B10.3 B
Slightly volatile

Virpax Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation880.1 K544.8 K584 K
Slightly volatile
Begin Period Cash Flow10.3 M19 M4.5 M
Slightly volatile
Total Cash From Financing Activities55.6 K58.5 K4.6 M
Pretty Stable
End Period Cash Flow11.9 M9.1 M5.2 M
Slightly volatile
Change To Netincome1.2 MM699.5 K
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Average Payables529557211.2 K
Slightly volatile
Cash Per Share7.427.80664.2115
Slightly volatile
Income Quality0.540.64870.6676
Very volatile
Current Ratio1.191.25141.8821
Slightly volatile
Graham Number34.1421.956920.2522
Slightly volatile
Debt To Assets3.683.877.8586
Pretty Stable
Ebt Per Ebit1.110.96811.0131
Slightly volatile
Quick Ratio1.191.25141.8821
Slightly volatile
Net Income Per E B T1.121.141.0447
Slightly volatile
Cash Ratio1.131.18811.7654
Slightly volatile
Debt Ratio3.683.877.8586
Pretty Stable

Virpax Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market CapM8.4 M202.4 M
Slightly volatile

Virpax Fundamental Market Drivers

Cash And Short Term Investments9.1 M

Virpax Upcoming Events

27th of March 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About Virpax Pharmaceuticals Financial Statements

Virpax Pharmaceuticals investors use historical fundamental indicators, such as Virpax Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Virpax Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue-941 K-893.9 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Virpax Stock Analysis

When running Virpax Pharmaceuticals' price analysis, check to measure Virpax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virpax Pharmaceuticals is operating at the current time. Most of Virpax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Virpax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virpax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Virpax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.